

Laurence Chaperot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3103963/publications.pdf>

Version: 2024-02-01

90
papers

6,011
citations

101496

36
h-index

71651

76
g-index

92
all docs

92
docs citations

92
times ranked

8530
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV-1 Nef Protein Affects Cytokine and Extracellular Vesicles Production in the GEN2.2 Plasmacytoid Dendritic Cell Line. <i>Viruses</i> , 2022, 14, 74.	1.5	0
2	Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80 ⁺ PDL1 ⁺) pDC subset negatively correlated with clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2022, 11, e1382.	1.7	6
3	Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment. <i>Cancer Research Communications</i> , 2022, 2, 577-589.	0.7	3
4	Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells. <i>Vaccines</i> , 2021, 9, 141.	2.1	5
5	Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol. <i>Respiratory Medicine and Research</i> , 2021, 80, 100845.	0.4	3
6	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and \hat{I} T cells in melanoma patients, which impacts clinical outcomes. <i>Clinical and Translational Immunology</i> , 2021, 10, e1329.	1.7	7
7	BDCA1 ⁺ cDC2s, BDCA2 ⁺ pDCs and BDCA3 ⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2020, 9, e1190.	1.7	16
8	Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. <i>Scientific Reports</i> , 2020, 10, 12767.	1.6	14
9	Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs. <i>Clinical and Translational Immunology</i> , 2020, 9, e1208.	1.7	3
10	T-cell receptor diversity as a prognostic biomarker in melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 612-624.	1.5	18
11	An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. <i>Oncolmmunology</i> , 2020, 9, 1738812.	2.1	38
12	Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and \hat{I} T Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints. <i>Frontiers in Immunology</i> , 2020, 11, 861.	2.2	17
13	Deciphering the Impact of Early-Life Exposures to Highly Variable Environmental Factors on Foetal and Child Health: Design of SEPAGES Couple-Child Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3888.	1.2	35
14	Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display. <i>Science Advances</i> , 2019, 5, eaaw2853.	4.7	29
15	Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept. <i>Journal of Translational Medicine</i> , 2019, 17, 312.	1.8	4
16	The features of circulating and tumor-infiltrating \hat{I} T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome. <i>Oncolmmunology</i> , 2019, 8, 1601483.	2.1	32
17	In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in CVHD: New insights in extracorporeal photopheresis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 450-460.	0.7	17
18	Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation. <i>Experimental Hematology and Oncology</i> , 2019, 8, 8.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2019, 10, 112.	2.2	22
20	The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94.	1.5	3
21	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0
22	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 364.	2.2	26
23	Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. <i>Journal of Experimental Medicine</i> , 2017, 214, 1471-1491.	4.2	81
24	Co-delivery of the NKT agonist α -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. <i>Oncolmmunology</i> , 2017, 6, e1339855.	2.1	45
25	Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 131-142.	2.9	47
26	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
27	Abstract 3686: Generation of an off-the-shelf cell-based platform (PDC-vac) for active antitumor immunotherapy. , 2017, , .		0
28	Death receptor 6 is a novel plasmacytoid dendritic cell-specific receptor and modulates type I interferon production. <i>Protein and Cell</i> , 2016, 7, 291-294.	4.8	4
29	NFATC3 promotes IRF7 transcriptional activity in plasmacytoid dendritic cells. <i>Journal of Experimental Medicine</i> , 2016, 213, 2383-2398.	4.2	26
30	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. <i>Blood</i> , 2016, 127, 3040-3053.	0.6	60
31	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016, 30, 764-778.	7.7	116
32	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0156063.	1.1	35
33	Characterization of species-specific genes regulated by E2-2 in human plasmacytoid dendritic cells. <i>Scientific Reports</i> , 2015, 5, 10752.	1.6	12
34	Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. <i>Immunity</i> , 2015, 43, 277-288.	6.6	47
35	SCARB2/LIMP-2 Regulates IFN Production of Plasmacytoid Dendritic Cells by Mediating Endosomal Translocation of TLR9 and Nuclear Translocation of IRF7. <i>Journal of Immunology</i> , 2015, 194, 4737-4749.	0.4	26
36	Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatfom. <i>Vaccine</i> , 2013, 31, 4338-4346.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Upregulation of Adhesion Molecules on Leukemia Targets Improves the Efficacy of Cytotoxic T Cells Transduced With Chimeric Anti-CD19 Receptor. <i>Journal of Immunotherapy</i> , 2013, 36, 181-189.	1.2	11
38	HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2395-2406.	0.3	37
39	Activation of the noncanonical NF- κ B pathway by HIV controls a dendritic cell immunoregulatory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14122-14127.	3.3	58
40	HIV triggers immunoregulatory dendritic cells and regulatory T cells through the non-canonical NF- κ B pathway. <i>Retrovirology</i> , 2012, 9, .	0.9	0
41	CD2AP/SHIP1 Complex Positively Regulates Plasmacytoid Dendritic Cell Receptor Signaling by Inhibiting the E3 Ubiquitin Ligase Cbl. <i>Journal of Immunology</i> , 2012, 189, 786-792.	0.4	39
42	Induction of Antiviral Cytotoxic T Cells by Plasmacytoid Dendritic Cells for Adoptive Immunotherapy of Posttransplant Diseases. <i>American Journal of Transplantation</i> , 2011, 11, 2613-2626.	2.6	26
43	Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 187, 538-552.	0.4	1,039
44	Innate Sensing of HIV-Infected Cells. <i>PLoS Pathogens</i> , 2011, 7, e1001284.	2.1	171
45	Photochemotherapy Induces a Faster Apoptosis of Alloreactive Activated T Cells Than of Nonalloreactive Resting T Cells in Graft Versus Host Disease. <i>Transplantation</i> , 2010, 90, 1232-1238.	0.5	34
46	Photochemotherapy Induces the Apoptosis of Monocytes Without Impairing Their Function. <i>Transplantation</i> , 2010, 89, 492-499.	0.5	26
47	Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. <i>European Journal of Dermatology</i> , 2010, 20, 016-023.	0.3	54
48	A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2010, 5, e10458.	1.1	47
49	Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-9.	3.0	8
50	Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1646-1656.	0.3	86
51	Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15181-15186.	3.3	284
52	TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. <i>Blood</i> , 2009, 114, 1794-1802.	0.6	94
53	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 624-636.	1.2	163
54	Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. <i>Leukemia</i> , 2009, 23, 698-707.	3.3	59

#	ARTICLE	IF	CITATIONS
55	Influenza recombinant vaccine: Matrix protein M1 on the platform of the adenovirus dodecahedron. <i>Vaccine</i> , 2009, 27, 7385-7393.	1.7	20
56	Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation. <i>Journal of Translational Medicine</i> , 2009, 7, 10.	1.8	15
57	P16-52. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. <i>Retrovirology</i> , 2009, 6, .	0.9	0
58	Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. <i>Haematologica</i> , 2009, 94, 1502-1512.	1.7	90
59	Plasmacytoid Dendritic Cells Capture and Cross-Present Viral Antigens from Influenza-Virus Exposed Cells. <i>PLoS ONE</i> , 2009, 4, e7111.	1.1	82
60	Dendritic cells and innate defense against tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 79-92.	3.2	49
61	Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells. <i>Cytotherapy</i> , 2008, 10, 642-649.	0.3	6
62	HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2008, 118, 3431-3439.	3.9	198
63	Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. <i>Vaccine</i> , 2007, 25, 3913-3921.	1.7	36
64	E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIPshort. <i>Cell Death and Differentiation</i> , 2006, 13, 260-272.	5.0	64
65	Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells. <i>Experimental Hematology</i> , 2006, 34, 1655-1662.	0.2	18
66	Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2006, 176, 248-255.	0.4	231
67	Mesenchymal stem cells induce apoptosis of activated T cells. <i>Leukemia</i> , 2005, 19, 1597-1604.	3.3	284
68	Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN- γ and Th1 chemokine production. <i>Journal of Leukocyte Biology</i> , 2005, 78, 954-966.	1.5	27
69	In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. <i>Leukemia</i> , 2004, 18, 1491-1498.	3.3	42
70	Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. <i>European Journal of Immunology</i> , 2004, 34, 418-426.	1.6	69
71	Preparation of purified lymphoma cells suitable for therapy. <i>Cytotherapy</i> , 2004, 6, 235-243.	0.3	6
72	Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. <i>Blood</i> , 2004, 105, 1256-1264.	0.6	83

#	ARTICLE	IF	CITATIONS
73	Mechanisms of action of extracorporeal photochemotherapy in the control of GVHD: involvement of dendritic cells. <i>Leukemia</i> , 2003, 17, 2061-2062.	3.3	20
74	Quality control for the validation of extracorporeal photopheresis process using the Vibertâ€“Lourmat UV-A irradiationâ€™s system. <i>Transfusion and Apheresis Science</i> , 2003, 28, 63-70.	0.5	26
75	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. <i>Blood</i> , 2003, 101, 949-954.	0.6	333
76	CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. <i>Haematologica</i> , 2003, 88, 941-55.	1.7	109
77	Clinical and biologic features of CD4+CD56+ malignancies. <i>Blood</i> , 2002, 99, 1556-1563.	0.6	404
78	Origin and filiation of human plasmacytoid dendritic cells. <i>Human Immunology</i> , 2002, 63, 1081-1093.	1.2	51
79	Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 2002, 119, 425-431.	1.2	10
80	Identification of a leukemic counterpart of the plasmacytoid dendritic cells. <i>Blood</i> , 2001, 97, 3210-3217.	0.6	356
81	Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. <i>Leukemia</i> , 2000, 14, 1667-1677.	3.3	34
82	From the Study of Tumor Cell Immunogenicity to the Generation of Antitumor Cytotoxic Cells in Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 2000, 38, 247-263.	0.6	7
83	Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkinâ€™s lymphoma. <i>Leukemia</i> , 1999, 13, 1428-1433.	3.3	20
84	Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkinâ€™s lymphomas. <i>Leukemia</i> , 1999, 13, 1548-1553.	3.3	17
85	Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkinâ€™s lymphomas. <i>Experimental Hematology</i> , 1999, 27, 479-488.	0.2	43
86	Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkinâ€™s lymphomas. <i>Experimental Hematology</i> , 1999, 27, 1185-1193.	0.2	14
87	Tumor B Cells From Non-Hodgkin's Lymphoma Are Resistant to CD95 (Fas/Apo-1)â€™ Mediated Apoptosis. <i>Blood</i> , 1998, 91, 2875-2885.	0.6	100
88	Relationships Between Susceptibility to LAK Cell-Mediated Lysis, Conjugate Formation and Expression of Adhesion Molecules in B-Cell Derived Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1997, 28, 133-143.	0.6	7
89	Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. <i>European Journal of Immunology</i> , 1995, 25, 3332-3341.	1.6	40
90	B cell sensitivity to autologous lak lysis in B lymphoma. <i>Biology of the Cell</i> , 1995, 84, 116-116.	0.7	0